Trans fatty acids and weight gain

Hugh Sinclair Unit of Human Nutrition, Department of Food and Nutritional Sciences, University of Reading, Reading, UK.
International journal of obesity (2005) (Impact Factor: 5). 03/2011; 35(3):315-24. DOI: 10.1038/ijo.2010.141
Source: PubMed


Increasing rates of obesity have stimulated research into possible contributing factors, including specific dietary components such as trans fatty acids (TFAs). This review considers the evidence for an association between TFA intake and weight gain. It concludes that there is limited but consistent evidence from epidemiological studies, and from a primate model, that increased TFA consumption may result in a small additional weight gain. Data from a long-term study in a primate model suggest that TFA may have a greater adipogenic effect than cis monounsaturated fatty acids; however, there are currently inadequate mechanistic data to provide a comprehensive and plausible explanation for any such metabolic differences between the types of fatty acids.

Download full-text


Available from: Abby K Thompson, Mar 20, 2014
  • Source
    • "The study was funded by National Science Foundation (Grant # CBET 0828292). [11] Shah, V., "
    [Show abstract] [Hide abstract]
    ABSTRACT: Oleic acid is a monounsaturated fatty acid and natural constituent of a number of foods, particularly vegetable oils. On the basis of proven beneficial health effects it is also a possible ingredient in processed functional foods. However, due to its high energy content it is not recommended to increase the consumption of any particular fat, but to substitute other lipids with oleic acid. While there is a well-established consensus that replacing saturated fats in the diet with oleic acid or other unsaturated fats contributes to the maintenance of normal blood cholesterol levels, a series of other effects has also been studied, including the modulation of inflammatory markers, blood pressure, insulin sensitivity, gastrointestinal functions and even various cancers. Commercial communication of such effects is only ethical where such effects are relevant to human health and proven using the highest possible standards, preferably with well-performed, double-blind, randomised, placebo-controlled human intervention trials. Most intervention studies investigating the health effects of oleic acid are performed using vegetable oils which also contain other fatty acids and minor constituents. This represents a possible confounding factor and makes interpretationsdifficult. In this chapter, the health effects of oleic acid are discussed together with the possibilities of using oleic-acid-related health claims on foods in commercial communications in the European Union.
    Full-text · Chapter · Jan 2014
  • Source
    • "Obesity is fast becoming a medical condition of global concern , particularly due to its consistent association with increased prevalence of cardiovascular diseases, diabetes mellitus, hypertension and some forms of cancers (Xia et al., 2010). It is now certain that genetic predisposition and consumption of high energy foods are the commonest pathogenetic factors (Thompson et al., 2011). Weight reduction, via dietary modulation is therefore the target of choice of many therapeutic measures. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This study was carried out to evaluate the anti-obesity effect of Vernonia amygdalina Del. (VA) supplemented diet. VA leaf powder was fed at 5% and 15% to diet-induced obese rats for 4 weeks and its effect compared with orlistat (5.14 mg/kg p.o.), an anti-obesity drug. Food intake, body and organ weights, total body fat, some lipid components and amino transaminase activities in serum, hepatocytes and brain; as well as serum glucose, were measured during or at end of the study. Result showed respective decrease of 12.78% and 38.51% in body weight gain, of VA fed rats against 17.45% of orlistat at end of study (P < 0.05); but with no effect on food intake. Total body fat was lowered by 28.04% and 30.02% vs. obese control rats (CDC) (P < 0.05). Furthermore, serum triacylglycerol (TG), serum and brain total cholesterol (TCHOL), were down regulated at 15% VA supplementation (P < 0.05). Serum glucose which increased in obese rats by 46.26% (P < 0.05) vs. NC, indicating intolerance, was restored by VA (38.75% and 34.65%) and orlistat (31.80%) vs. CDC (P < 0.05). VA diet also exerted hepato-protection, via lowering serum alanine amino transaminase (ALT) (41.35% and 27.13%) and aspartate amino transaminase (AST) (17.09% and 43.21%) activities (P < 0.05). Orlistat had no effect on these enzymes. Histology of adipose tissue corroborated the changes on total body fat. We concluded that, diet supplemented with VA can attenuate dietary obesity as well as ameliorates the potential risks of hepato-toxicity and glucose intolerance associated with obesity.
    Full-text · Article · Jul 2012 · Saudi Journal of Biological Sciences
  • Source

    Full-text · Article · May 2011 · Canadian Medical Association Journal
Show more